Dr. Farber is considered an opinion leader and internationally recognized expert in the field of pulmonary hypertension. He is a Professor in the Department of Medicine and attends in the Medical Intensive Care Unit and on the Pulmonary Consultation Service at Boston Medical Center. He also oversees the care of all patients with Pulmonary Hypertension at Boston Medical Center.
Dr. Farber’s research focuses on endothelial cell biology, in particular, the response of the pulmonary vasculature to injury. He has extensive government and private funding and is an NIH-funded Principle Investigator on several grants. He is a member of several research groups both within the Pulmonary Center and in other divisions within the Department of Medicine: the Pulmonary Vascular Biology Group (Pulmonary Center); the Center for Excellence in Sickle Cell Disease (Hematology), the Scleroderma Vascular Disease Group (Rheumatology) and Pulmonary Vascular/Left Ventricular Study Group (Cardiology). Dr. Farber’s laboratory is investigating the response of the pulmonary vasculature in different etiologies of pulmonary hypertension using genomic and proteomic approaches to identify unique molecules as potential targets for new therapies for pulmonary hypertension associated with sickle cell disease, with scleroderma, and with left ventricular diastolic dysfunction.
Dr. Farber’s team is developing a database and registry of sickle cell patients with pulmonary hypertension (see Dr. Elizabeth Klings’ faculty profile) as well as a database and registry of scleroderma patients with various forms of pulmonary disease including pulmonary hypertension. They are participating in numerous multi-center clinical trials of new therapies for pulmonary hypertension and have several single-site trials for novel proof of concept therapies for pulmonary hypertension.
- George Washington University, MD
- Duke University, BS
- Published on 4/12/2018
Farber HW, McDermott S, Witkin AS, Kelly NP, Miloslavsky EM, Stone JR. Case 11-2018: A 48-Year-Old Woman with Recurrent Venous Thromboembolism and Pulmonary Artery Aneurysm. N Engl J Med. 2018 Apr 12; 378(15):1430-1438. PMID: 29641962.
- Published on 4/1/2018
Farber HW, Benza RL. Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials? Am J Respir Crit Care Med. 2018 Apr 01; 197(7):843-845. PMID: 29373796.
- Published on 3/17/2018
Farber HW, Badesch DB, Benza RL, Elliott CG, Frantz RP, McGoon MD, Selej M, Zhao C, Frost AE. Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. J Heart Lung Transplant. 2018 Mar 17. PMID: 29653800.
- Published on 3/1/2018
Benza RL, Farber HW, Frost A, Grünig E, Hoeper MM, Busse D, Meier C, Nikkho S, Ghofrani HA. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant. 2018 Mar 01. PMID: 29580746.
- Published on 1/31/2018
Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Zhao C, Mink DR, Selej M, Benza RL. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. Chest. 2018 Jan 31. PMID: 29355551.
- Published on 1/24/2018
Abston E, Farber H. Pulmonary Cavity From Mycobacterium malmoense in an HIV-Infected Patient: Complicated by Bronchopleural Fistula. Open Forum Infect Dis. 2018 Feb; 5(2):ofy023. PMID: 29450215.
- Published on 11/21/2017
Miller DP, Farber HW. Pulmonary Veno-Occlusive Disease: Welcome to the PAHty (Bostonian for Party). Circulation. 2017 Nov 21; 136(21):2034-2036. PMID: 29158214.
- Published on 11/11/2017
Benza RL, Farber HW, Frost A, Ghofrani HA, Gómez-Sánchez MA, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper MM. REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. J Heart Lung Transplant. 2018 Apr; 37(4):513-519. PMID: 29223470.
- Published on 11/6/2017
Chakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, Frantz RP, Selej M, Zhao C, Mink DR, Farber HW. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. J Heart Lung Transplant. 2017 Nov 06. PMID: 29174533.
- Published on 10/2/2017
Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. J Heart Lung Transplant. 2018 Mar; 37(3):401-408. PMID: 29096938.
View 199 more publications: View full profile at BUMC